Bridging the gap between lab-scale innovation and commercial reality. Specialized in ECS therapeutics, synthetic biology, and R&D operational architecture.
Initiate Strategy SessionFounded and led through acquisition by Lygos. Secured $7M+ in funding and managed the full IP diligence and technical integration of the first yeast-based cannabinoid platform.
Built a state-of-the-art San Diego innovation center. Negotiated multi-million dollar Joint Development Agreements with international public companies.
Leading technical diligence and IND-enabling studies for gut-targeted small molecule platforms. Specialized in metabolic and inflammation therapeutic strategy.